ѻý

Obesity Associated With Faster MS Disease Progression

<ѻý class="mpt-content-deck">— Increased risk of physical, psychological, cognitive decline
MedpageToday

WEST PALM BEACH, Fla. -- Obesity in multiple sclerosis (MS) was tied to faster worsening of disability and an increased risk of physical, psychological, and cognitive decline, a prospective cohort study showed.

Compared with normal weight, obesity was associated with a faster increase in scores on the Expanded Disability Status Scale (, which ranges from 0-10 with higher numbers reflecting greater disability, reported Lars Alfredsson, PhD, of the Karolinska Institute in Stockholm, Sweden, in a presentation at the ACTRIMS Forum 2024, the annual meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis.

The risk of reaching EDSS 3 was 41% higher in MS patients with obesity (hazard ratio [HR] 1.41, 95% CI 1.51-1.72). The risk of reaching EDSS 4 was 31% higher (HR 1.31, 95% 1.03-1.68).

Obesity also was associated with an increased risk of self-reported physical quality of life (HR 1.40, 95% CI 1.18-1.67) and psychological quality of life (HR 1.24, 95% CI 1.04-1.46), and with cognitive disability worsening (HR 1.47, 95% CI 1.08-2.01).

Several studies have shown obesity may be a risk factor for developing MS, but few have drawn definitive conclusions about the role of obesity in MS progression, Alfredsson noted. One , however, found that obesity in newly diagnosed MS patients was linked with a significantly higher risk of reaching EDSS 3 over 6 years, compared with normal weight.

"Patients commonly ask about ways they can impact the course of MS using lifestyle interventions," said Robert Bermel, MD, of the Cleveland Clinic in Ohio, who wasn't involved with the study.

"Based on this and other studies, weight loss can be recommended as a lifestyle intervention for obese patients with MS, in addition to treatment with disease-modifying therapy," Bermel told ѻý in an email.

He and Alfredsson also brought up the potential study of GLP-1 agonists like semaglutide (Ozempic, Wegovy) for therapeutic weight loss in patients with MS.

Differences in disease progression were not as stark for patients categorized as overweight, Alfredsson reported. In patients who did not change BMI category during the study period, the differences were greater than among the overall group, with higher risks of reaching EDSS 3, physical and psychological worsening, and cognitive disability worsening.

The study also found that patients in the overweight and obesity groups had a slightly increased risk of new lesions on MRI post-diagnosis.

Data came from 3,249 patients in the from 2005-2019, and from questionnaires patients answered at study inclusion and later in 2021. Patients were categorized by body mass index (BMI) at diagnosis and followed for up to 15 years post-diagnosis. Patients with a BMI of 18.5-24.99 were categorized as normal, 25-30 were considered overweight, and those with a BMI over 30 were classified as having obesity.

Most patients (74%) were female and mean baseline age was 37.8 years. In addition to EDSS, the study assessed scores from the and the .

Limitations included self-reported data on BMI and potential residual confounding from factors not accounted for by the study. BMI alone may be an because it does not directly assess body fat.

  • author['full_name']

    Sophie Putka is an enterprise and investigative writer for ѻý. Her work has appeared in the Wall Street Journal, Discover, Business Insider, Inverse, Cannabis Wire, and more. She joined ѻý in August of 2021.

Disclosures

Funding for this study came from the Swedish Research Council, Swedish Brain Foundation, and Region Stockholm.

Alfredsson did not report disclosures.

Primary Source

Americas Committee for Treatment and Research in Multiple Sclerosis

Alfredsson L, et al "Obesity negatively affects disease progression, cognitive functioning, and quality of life in people with multiple sclerosis" ACTRIMS Forum 2024; abstract CE1.1.